Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PBM Action Lags In Congress And At FTC As Targeting Commercial Plans Divides Republicans

Executive Summary

PBM reform isn’t expected to ride along with the next government funding packages, which could push any prospect of legislative reform closer to 2025. Meanwhile FTC says it is facing difficulty getting all the information for its investigation. 

You may also be interested in...



Bernie Gets Mostly Pharma-Friendly Drug Pricing Results

Changes to inhaler pricing may be more ‘business as usual’ for the drug industry than the Vermont senator wants to let on. FTC, meanwhile, is keeping the patent pressure on Teva, the only inhaler manufacturer to not act following Sanders’ investigation.

Mark Cuban: Pharma’s Secret Weapon In The Fight Against PBMs

The well-known businessman and TV personality told the White House that the US needs to ‘stop doing business with the big three PBMs,’ helping to fight the drug industry’s battle against the middlemen with a friendlier face not associated directly with the brand industry.

Strong House Vote On PBM, Generics Bill Sets Stage For Early 2024 Action

Easy House passage of a health package that includes PBM reforms and policies to help generic drug makers likely creates enough momentum to spur bicameral action. Overall policy still a work in progress – presenting last-minute opportunities for other drug pricing reforms to get tacked on.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS149864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel